AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31

20/20 Biolabs, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.26−0.00 (-0.12%)

Close on Oct 19, 2026

Market cap: $2.81M
P/E (TTM): –
Dividend yield: –

20/20 Biolabs, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31
Revenue	2.05	1.75
Cost of Revenue	1.44	1.39
Gross Profit	0.60	0.36
Research & Development	0.59	1.26
Selling, General & Admin	3.34	4.76
Advertising Expenses	0.17	0.53
Operating Expenses	3.94	6.04
Operating Income	-3.33	-5.68
Interest Expense	0.16	0.01
Interest & Investment Income	0.02	0.08
Other Non-Operating Income	-0.41	0.13
Asset Impairment Charges	–	0.02
Net Income	-3.74	-5.55
EPS (Basic)(per share)	-0.76	-1.16
EPS (Diluted)(per share)	-0.76	-1.16
Shares Outstanding (Basic, Weighted)(shares)	4.93	4.80
Shares Outstanding (Diluted, Weighted)(shares)	4.93	4.80
EBITDA	-3.27	-5.56

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: 29.6%
Operating margin: -162.9%
Net margin: -182.8%
Return on equity, FY2025: -503.1%

Financial strength

Current ratio: 1.99
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 178.2%

Valuation

P/E ratio: –
Price to sales: 1.37
Price to book: 1.73
Dividend yield: –